WASHINGTON – A new study published in Cancer Discovery, a monthly peer-reviewed medical journal released by the American Association for Cancer Research (AACR), has shown promising results from the phase 2 clinical trial of the drug, Trametinib, in treating relapsed or refractory (R/R) juvenile myelomonocytic leukaemia (JMML).
